Rapid Influenza Diagnostic Tests (RIDT) Market

By Test;

Traditional Diagnostic Test, Molecular Diagnostic Tests, and Others

By Type;

Type A Flu, Type B Flu, and Type C Flu

By Molecular;

PCR, INAAT- NASBAT, and TMABAS

By Product Type;

RIDT For Influenza A and RIDT for Influenza B

By End-Use;

Hospitals, Diagnostics Centers, Research Laboratories, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn964974762 Published Date: August, 2025

Rapid Influenza Diagnostic Tests (RIDT) Market Overview

Rapid Influenza Diagnostic Tests (RIDT) Market (USD Million)

Rapid Influenza Diagnostic Tests (RIDT) Market was valued at USD 1,260.35 million in the year 2024. The size of this market is expected to increase to USD 2,223.80 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.5%.


Rapid Influenza Diagnostic Tests (RIDT) Market

*Market size in USD million

CAGR 8.5 %


Study Period2025 - 2031
Base Year2024
CAGR (%)8.5 %
Market Size (2024)USD 1,260.35 Million
Market Size (2031)USD 2,223.80 Million
Market ConcentrationMedium
Report Pages300
1,260.35
2024
2,223.80
2031

Major Players

  • Roche Diagnostics
  • Abbott Laboratories
  • Quidel Corporation
  • Thermo Fisher Scientific
  • BD (Becton, Dickinson and Company)
  • DiaSorin
  • Luminex Corporation
  • Meridian Bioscience
  • Cepheid
  • Sekisui Diagnostics

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Rapid Influenza Diagnostic Tests (RIDT) Market

Fragmented - Highly competitive market without dominant players


The Rapid Influenza Diagnostic Tests (RIDT) Market is gaining momentum as healthcare providers increasingly rely on fast and efficient point-of-care diagnostics. With more than 65% of medical institutions turning to RIDTs, the emphasis on reducing diagnostic wait times and improving patient care is evident. This shift is opening fresh opportunities for product innovation and technological expansion across medical settings. The market is evolving with a strong focus on streamlined testing solutions and cost-effective strategies.

Influenza’s Growing Impact Sparks Innovation
As over 70% of flu-related screenings depend on immediate results, RIDTs play a pivotal role in early detection. The rising burden of seasonal influenza has prompted continual innovation in test design and delivery. Many companies are deploying targeted strategies involving collaboration with research groups to launch highly sensitive formats. These efforts are reinforcing the market’s growth trajectory and building a strong future outlook for diagnostic solutions.

Boost from Emerging Diagnostic Technologies
Innovative molecular RIDTs are now delivering over 60% higher accuracy, driving broader acceptance in clinical practice. These technological advancements are pushing stakeholders to refine their growth strategies by investing in automation and precision tools. The increase in digital testing platforms reflects a broader industry push toward streamlined operations and smarter diagnostics, ensuring better patient outcomes.

Promising Market Expansion Pathways
The Rapid Influenza Diagnostic Tests (RIDT) Market is on a promising growth path, with usage expected to exceed 75% across healthcare systems. Stakeholders are proactively exploring opportunities to boost output, optimize delivery channels, and enhance diagnostic availability. Supported by continuous technological evolution, solid partnership models, and increasing demand, the sector's expansion and future growth potential remain strong.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Test
    2. Market Snapshot, By Type
    3. Market Snapshot, By Molecular
    4. Market Snapshot, By Product Type
    5. Market Snapshot, By End-Use
    6. Market Snapshot, By Region
  4. Rapid Influenza Diagnostic Tests (RIDT) Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Seasonal outbreaks demand
        2. Rapid result necessity
        3. Public health awareness
        4. Point-of-care convenience
        5. Technological advancements
      2. Restraints
        1. Accuracy concerns persist
        2. Regulatory compliance challenges
        3. Cost implications affect
        4. Variability in performance
        5. Emerging competitor pressures
      3. Opportunities
        1. Pandemic preparedness initiatives
        2. Emerging markets expansion
        3. Integration with telemedicine
        4. Multiplexed testing development
        5. Ongoing R&D innovations
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Rapid Influenza Diagnostic Tests (RIDT) Market,By Test, 2021 - 2031 (USD Million)
      1. Traditional Diagnostic Test
      2. Molecular Diagnostic Tests
      3. Others
    2. Rapid Influenza Diagnostic Tests (RIDT) Market,By Type, 2021 - 2031 (USD Million)
      1. Type A Flu
      2. Type B Flu
      3. Type C Flu
    3. Rapid Influenza Diagnostic Tests (RIDT) Market,By Molecular, 2021 - 2031 (USD Million)
      1. PCR
      2. INAAT- NASBAT
      3. TMABAS
    4. Rapid Influenza Diagnostic Tests (RIDT) Market,By Product Type, 2021 - 2031 (USD Million)
      1. RIDT for Influenza A
      2. RIDT for Influenza B
    5. Rapid Influenza Diagnostic Tests (RIDT) Market, By End-Use, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Diagnostics centers
      3. Research laboratories
      4. Others
    6. Rapid Influenza Diagnostic Tests (RIDT) Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Roche Diagnostics
      2. Abbott Laboratories
      3. Quidel Corporation
      4. Thermo Fisher Scientific
      5. BD (Becton, Dickinson and Company)
      6. DiaSorin
      7. Luminex Corporation
      8. Meridian Bioscience
      9. Cepheid
      10. Sekisui Diagnostics
  7. Analyst Views
  8. Future Outlook of the Market